Pilot Study of the Effect of Surgical Menopause on Bone Mineral Density and Quality in Patients with Gynecological Malignancies

Overview

Journal J Obstet Gynaecol Res

Specialty Gynecology & Obstetrics

Date 2024 Nov 12

PMID 39530312

Authors

Kanae Matsuno

Kazu Ueda

Mitsuru Saito

Misato Kamii

Akina Tsuda

Ayako Kawabata

Asuka Morikawa

Aikou Okamoto

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effects of surgical menopause on bone mineral density and bone quality because bilateral salpingo-oophorectomy for the treatment of gynecological malignancies is common even in premenopausal patients. This study is prospective one of bone mineral density and quality measurements after surgery for perimenopausal gynecologic malignancies.

Methods: In 50 women who underwent surgical menopause for a diagnosis of gynecological malignancies, bone mineral density (BMD), blood levels of tartrate-resistant acid phosphatase 5b (TRACP-5b) and bone-specific alkaline phosphatase (BAP) as bone metabolism markers, and urinary pentosidine level as bone quality marker were measured before surgery and at multiple points up to 24 months after surgery.

Results: In a group of 22 patients who did not undergo hormone replacement therapy (HRT) (HRT- group), BMD of the lumbar spine and total hip continued to decrease significantly from 6 months postoperatively. Percentages of changes in BMD progressively increased over time after surgery. TRACP-5b and urinary pentosidine levels significantly increased 6 months postoperatively compared with preoperative levels. Comparisons between 10 patients who underwent HRT (HRT+ group) and the HRT- group revealed significant reductions in the percentage of change in lumbar spine BMD only and TRACP-5b and urinary pentosidine levels 12 months postoperatively in the former group.

Conclusions: In this pilot study, we showed that BMD and bone-related markers are altered in patients with surgical menopause. It also suggested that HRT may reduce these influences on bone metabolism.

Citing Articles

Pilot study of the effect of surgical menopause on bone mineral density and quality in patients with gynecological malignancies.

Matsuno K, Ueda K, Saito M, Kamii M, Tsuda A, Kawabata A J Obstet Gynaecol Res. 2024; 51(1):e16141.

PMID: 39530312 PMC: 11635186. DOI: 10.1111/jog.16141.

References

Gokmen O, Seckin N, Sener A, Ozaksit G, Ekmekci S . A study of premature ovarian failure in Turkish women. Gynecol Endocrinol. 1995; 9(4):283-7. DOI: 10.3109/09513599509160460. View

Saito M, Fujii K, Marumo K . Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int. 2006; 79(3):160-8. DOI: 10.1007/s00223-006-0035-1. View

Nishio K, Tanabe A, Maruoka R, Nakamura K, Takai M, Sekijima T . Bone mineral loss induced by anticancer treatment for gynecological malignancies in premenopausal women. Endocr Connect. 2013; 2(1):11-7. PMC: 3680962. DOI: 10.1530/EC-12-0043. View

Cauley J, Robbins J, Chen Z, Cummings S, Jackson R, LaCroix A . Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290(13):1729-38. DOI: 10.1001/jama.290.13.1729. View

Lee S, Yeo S, Oh I, Yeo J, Park D . Bone mineral density in women treated for various types of gynecological cancer. Asia Pac J Clin Oncol. 2016; 12(4):e398-e404. DOI: 10.1111/ajco.12584. View

Stavraka C, Maclaran K, Gabra H, Agarwal R, Ghaem-Maghami S, Taylor A . A study to evaluate the cause of bone demineralization in gynecological cancer survivors. Oncologist. 2013; 18(4):423-9. PMC: 3639529. DOI: 10.1634/theoncologist.2012-0416. View

Wei R, Jung B, Manzano W, Sehgal V, Klempner S, Lee S . Bone mineral density loss in thoracic and lumbar vertebrae following radiation for abdominal cancers. Radiother Oncol. 2016; 118(3):430-6. DOI: 10.1016/j.radonc.2016.03.002. View

Pouilles J, Tremollieres F, Ribot C . The effects of menopause on longitudinal bone loss from the spine. Calcif Tissue Int. 1993; 52(5):340-3. DOI: 10.1007/BF00310195. View

McClung M . Sclerostin antibodies in osteoporosis: latest evidence and therapeutic potential. Ther Adv Musculoskelet Dis. 2017; 9(10):263-270. PMC: 5613857. DOI: 10.1177/1759720X17726744. View

10.

Saito M, Marumo K . Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus. Osteoporos Int. 2009; 21(2):195-214. DOI: 10.1007/s00198-009-1066-z. View

11.

Uezono H, Tsujino K, Moriki K, Nagano F, Ota Y, Sasaki R . Pelvic insufficiency fracture after definitive radiotherapy for uterine cervical cancer: retrospective analysis of risk factors. J Radiat Res. 2013; 54(6):1102-9. PMC: 3823778. DOI: 10.1093/jrr/rrt055. View

12.

Bone H, Greenspan S, McKeever C, Bell N, Davidson M, Downs R . Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000; 85(2):720-6. DOI: 10.1210/jcem.85.2.6393. View

13.

Johnell O, Kanis J, Oden A, Sernbo I, Redlund-Johnell I, Petterson C . Mortality after osteoporotic fractures. Osteoporos Int. 2003; 15(1):38-42. DOI: 10.1007/s00198-003-1490-4. View

14.

Bliuc D, Nguyen N, Milch V, Nguyen T, Eisman J, Center J . Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA. 2009; 301(5):513-21. DOI: 10.1001/jama.2009.50. View

15.

Nicosia S, Meadows A . Gonadal effects of cancer therapy in girls. Cancer. 1985; 55(10):2364-72. DOI: 10.1002/1097-0142(19850515)55:10<2364::aid-cncr2820551011>3.0.co;2-e. View

16.

Chu P, Chao T, Lin Y, Janckila A, Yam L . Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis. 2003; 41(5):1052-9. DOI: 10.1016/s0272-6386(03)00203-8. View

17.

Shapses S, Riedt C . Bone, body weight, and weight reduction: what are the concerns?. J Nutr. 2006; 136(6):1453-6. PMC: 4016235. DOI: 10.1093/jn/136.6.1453. View

18.

Shiraki M, Urano T, Kuroda T, Saito M, Tanaka S, Miyao-Koshizuka M . The synergistic effect of bone mineral density and methylenetetrahydrofolate reductase (MTHFR) polymorphism (C677T) on fractures. J Bone Miner Metab. 2008; 26(6):595-602. DOI: 10.1007/s00774-008-0878-9. View

19.

Nishizawa Y, Ohta H, Miura M, Inaba M, Ichimura S, Shiraki M . Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). J Bone Miner Metab. 2012; 31(1):1-15. DOI: 10.1007/s00774-012-0392-y. View

20.

Hartmann B, Kirchengast S, Albrecht A, Laml T, Soregi G, Huber J . Androgen serum levels in women with premature ovarian failure compared to fertile and menopausal controls. Gynecol Obstet Invest. 1997; 44(2):127-31. DOI: 10.1159/000291503. View